High Density of CD16+ Tumor-Infiltrating Immune Cells in Recurrent Ovarian Cancer Is Associated with Enhanced Responsiveness to Chemotherapy and Prolonged Overall Survival.
CD16
biomarker
immunohistochemistry
ovarian cancer
prognosis
recurrence
tissue microarray
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Nov 2021
18 Nov 2021
Historique:
received:
15
10
2021
revised:
10
11
2021
accepted:
16
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Ovarian cancer (OC) is the most aggressive and fatal malignancy of the female reproductive system. Debulking surgery with adjuvant chemotherapy represents the standard treatment, but recurrence rates are particularly high. Over the past decades, the association between the immune system and cancer progression has been extensively investigated. However, the interaction between chemotherapy and cancer immune infiltration is still unclear. In this study, we examined the prognostic role of CD16 expression in OC, as related to the effectiveness of standard adjuvant chemotherapy treatment. We analyzed the infiltration by immune cells expressing CD16, a well-characterized natural killer (NK) and myeloid cell marker, in a tissue microarray (TMA) of 47 patient specimens of primary OCs and their matching recurrences by immunohistochemistry (IHC). We analyzed our data first in the whole cohort, then in the primary tumors, and finally in recurrences. We focused on recurrence-free survival (RFS), overall survival (OS), and chemosensitivity. Chemosensitivity was defined as RFS of more than 6 months. There was no significant correlation between CD16 expression and prognosis in primary carcinomas. However, interestingly, a high density of CD16-expressing tumor-infiltrating immune cells (TICs) in recurrent carcinoma was associated with better RFS ( The high density of CD16-expressing TICs in recurrent ovarian cancer is associated with a better RFS and OS, thereby suggesting a previously unsuspected interaction between standard OC chemotherapy and immune cell infiltration.
Sections du résumé
BACKGROUND
BACKGROUND
Ovarian cancer (OC) is the most aggressive and fatal malignancy of the female reproductive system. Debulking surgery with adjuvant chemotherapy represents the standard treatment, but recurrence rates are particularly high. Over the past decades, the association between the immune system and cancer progression has been extensively investigated. However, the interaction between chemotherapy and cancer immune infiltration is still unclear. In this study, we examined the prognostic role of CD16 expression in OC, as related to the effectiveness of standard adjuvant chemotherapy treatment.
METHODS
METHODS
We analyzed the infiltration by immune cells expressing CD16, a well-characterized natural killer (NK) and myeloid cell marker, in a tissue microarray (TMA) of 47 patient specimens of primary OCs and their matching recurrences by immunohistochemistry (IHC). We analyzed our data first in the whole cohort, then in the primary tumors, and finally in recurrences. We focused on recurrence-free survival (RFS), overall survival (OS), and chemosensitivity. Chemosensitivity was defined as RFS of more than 6 months.
RESULTS
RESULTS
There was no significant correlation between CD16 expression and prognosis in primary carcinomas. However, interestingly, a high density of CD16-expressing tumor-infiltrating immune cells (TICs) in recurrent carcinoma was associated with better RFS (
CONCLUSIONS
CONCLUSIONS
The high density of CD16-expressing TICs in recurrent ovarian cancer is associated with a better RFS and OS, thereby suggesting a previously unsuspected interaction between standard OC chemotherapy and immune cell infiltration.
Identifiants
pubmed: 34830938
pii: cancers13225783
doi: 10.3390/cancers13225783
pmc: PMC8616362
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2011 Feb 20;29(6):601-3
pubmed: 21245434
Gynecol Oncol. 2011 Aug;122(2):350-5
pubmed: 21546066
Immunol Rev. 2006 Dec;214:73-91
pubmed: 17100877
Int J Gynecol Cancer. 2011 Jan;21(1):58-65
pubmed: 21178570
Acta Oncol. 2020 Nov;59(11):1365-1373
pubmed: 32692270
J Clin Oncol. 2003 Sep 1;21(17):3194-200
pubmed: 12860964
Int J Cancer. 2017 Jun 1;140(11):2451-2460
pubmed: 28257597
Sci Immunol. 2017 Jan 6;2(7):
pubmed: 28783667
Oncogene. 2005 Feb 3;24(6):1053-65
pubmed: 15558012
Am J Pathol. 2004 May;164(5):1511-8
pubmed: 15111296
J Immunol. 2007 Dec 15;179(12):8454-62
pubmed: 18056392
J Clin Pathol. 2007 Oct;60(10):1112-6
pubmed: 17182662
Eur J Cancer. 2012 Aug;48(12):1774-80
pubmed: 22305465
Oncogene. 2015 Jul;34(27):3605-16
pubmed: 25263447
J Cancer Res Clin Oncol. 2020 Jan;146(1):127-136
pubmed: 31853662
Arch Gynecol Obstet. 2014 Nov;290(5):839-42
pubmed: 25082067
J Pathol. 2001 Sep;195(1):72-9
pubmed: 11568893
Int J Gynecol Cancer. 2011 Feb;21(2):289-95
pubmed: 21270612
N Engl J Med. 1995 Mar 9;332(10):629-34
pubmed: 7845426
Oncoimmunology. 2017 Feb 10;6(3):e1290037
pubmed: 28405525
Clin Cancer Res. 2005 Sep 1;11(17):6300-10
pubmed: 16144934
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Blood. 2006 Jan 1;107(1):159-66
pubmed: 16150947
PLoS One. 2013 May 29;8(5):e64814
pubmed: 23734221
J Cancer Res Clin Oncol. 2013 Aug;139(8):1295-302
pubmed: 23624523
N Engl J Med. 2004 Dec 9;351(24):2489-97
pubmed: 15590951
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
J Clin Oncol. 2008 Apr 10;26(11):1789-96
pubmed: 18347005
Cell Oncol (Dordr). 2017 Apr;40(2):105-118
pubmed: 27981507
Sci Rep. 2021 Jan 12;11(1):775
pubmed: 33436863
Cell. 2006 Jan 27;124(2):263-6
pubmed: 16439202
Immunology. 2007 Nov;122(3):418-29
pubmed: 17617155
Immunol Rev. 2008 Apr;222:155-61
pubmed: 18364000
Clin Cancer Res. 2019 Aug 1;25(15):4634-4643
pubmed: 31053601
Med Electron Microsc. 2003 Mar;36(1):9-17
pubmed: 12658347
BMC Immunol. 2020 Aug 8;21(1):46
pubmed: 32770940
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5640-4
pubmed: 10318937
Ann Oncol. 2011 Jan;22(1):39-48
pubmed: 20643862
Am J Pathol. 2002 Apr;160(4):1223-8
pubmed: 11943707
Sci Rep. 2016 Sep 27;6:34310
pubmed: 27670158
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Res. 1998 Aug 15;58(16):3491-4
pubmed: 9721846
Cancer Immunol Res. 2018 Oct;6(10):1174-1185
pubmed: 30018043
Int J Gynaecol Obstet. 2014 Jan;124(1):1-5
pubmed: 24219974
Nat Rev Cancer. 2012 Mar 15;12(4):298-306
pubmed: 22419253
PLoS Med. 2008 Dec 2;5(12):e232
pubmed: 19053170
Clin Cancer Res. 2013 Mar 1;19(5):961-8
pubmed: 23307860
Dis Markers. 2014;2014:792183
pubmed: 25609852
Clin Cancer Res. 2017 Jul 15;23(14):3847-3858
pubmed: 28108544
Ann Oncol. 2017 Nov 1;28(suppl_8):viii51-viii56
pubmed: 29232464
Oncogene. 2010 Feb 25;29(8):1093-102
pubmed: 19946335
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Int J Cancer. 2011 Jun 1;128(11):2663-72
pubmed: 20715106
Blood. 2007 Oct 1;110(7):2561-4
pubmed: 17475906